Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer

Fan, Chung-Wei; Kuo, Yung-Bin; Lin, Geng-Pin; Chen, Si-Min; Chang, Shih-Hsien; Li, Boan; Chan, Err–Cheng

doi:10.1016/j.cca.2017.10.022

Cited by 16 publications

(14 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the reference lists of review articles and related articles were manually screened to identify additional studies. Finally, a total of 80 articles involving 145 specific tumour‐associated autoantibodies detected in patients with CRC were selected (Table ) . Anti‐p53 antibody was the most commonly studied autoantibody, followed by MUC1, CEA, c‐myc, survivin, HDAC5, p62, ANXA4, koc, NY‐CO‐16, NY‐ESO‐1, RPH3AL, cyclin B, Imp1, IMPDH2 and MAGEA3.…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, in order to further explore the potential diagnostic efficacy of autoantibodies, we performed a meta‐analysis of studies that assessed the diagnostic relevance of p53 autoantibody for CRC. After exclusion of 14 studies in which the blood samples were not collected before initiation of treatment (Table ), 27 studies published in 24 articles mentioning anti‐p53 were included in the meta‐analysis (Table ).…”

Section: Resultsmentioning

confidence: 99%

“…Simultaneously, the positive results of p53 autoantibody may indicate an increased risk of cancer. In addition, it has been reported that the level of p53 autoantibody in blood is significantly higher in CRC patients than in healthy controls . As for the potential use of antibody for early detection of CRC, Ushigome found that the positive rates of the four antibodies (p53, RalA, HSP70 and Galectin1) did not increase depending on stage progression; this implies that the autoantibody may facilitate early detection of CRC regardless of the tumour stage.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

Serum autoantibodies against tumour-associated antigens are promising biomarkers for diagnosis of cancer. This review summarizes the available evidence pertaining to the diagnostic potential of autoantibodies studied in the context of colorectal cancer (CRC). A systematic literature search was conducted in three databases (PubMed, Cochrane Library and Embase). Data pertaining to a total of 145 autoantibodies published in 80 articles were reviewed. Of these, anti-p53 antibody was the most commonly studied autoantibody; thus, we performed a meta-analysis on anti-p53 antibody in 24 articles. According to the cut-off values used to determine positivity for anti-p53 antibody, we divided the included studies into five groups. Owing to the presence of threshold effect in groups 4 and 5 and non-threshold effect in groups 1 and 2, pooled analysis focused on group 3 using a fixed-effects model (Mantel-Haenszel). Group 3, determining the cut-off value based on the value of p53 antibody titre index, was comprised of five articles including 733 patients with CRC and 172 controls (126 healthy individuals and 46 benign diseases). The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and summary area under the receiver operating characteristic curves were 0. 21, 0.99, 12.26, 0.80, 15.46 and 0.87, respectively. Serum anti-p53 autoantibody may potentially help distinguish CRC from healthy controls or benign diseases; however, it should be used in combination with other indicators due to the low sensitivity. Our study provides insights for further exploration of the optimal combination of different tumour-associated antigens or autoantibodies for diagnosis of CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…55,56 Furthermore, STC2 was considered to be a diagnostic gene of lung cancer, as well as a promising prognostic gene of high-grade serous ovarian cancer. 57,58 RPH3AL may be related to the diagnosis of colorectal cancer 59 and, in another study, it was determined that…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, STC2 was considered to be a diagnostic gene of lung cancer, as well as a promising prognostic gene of high‐grade serous ovarian cancer . RPH3AL may be related to the diagnosis of colorectal cancer and, in another study, it was determined that MYEVO was a factor related to the survival of multiple myeloma patients . TREM1 correlated with aggressive tumor behavior and recurrence, and was a relevant independent predictor of poor patient survival .…”

Section: Discussionmentioning

confidence: 99%

Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma

Zhang

Bing

Yan

et al. 2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background Gene signatures for predicting the outcome of lung squamous cell carcinoma (LUSC) have been employed for many years. However, various signatures have been applied in clinical practice. Therefore, in the present study, we aimed to filter out an effective LUSC prognostic gene signature by simultaneously integrating mRNA and microRNA (miRNA). Methods First, based on data from the Cancer Genome Atlas (TCGA) (https://www.cancer.gov/tcga), mRNAs and miRNAs that were related to overall survival of LUSC were obtained by the least absolute shrinkage and selection operator method. Subsequently, the predicting effect was tested by time‐dependent receiver operating characteristic curve analysis and Kaplan–Meier survival analysis. Next, related clinical indices were added to evaluate the efficiency of the selected gene signatures. Finally, validation and comparison using three independent gene signatures were performed using data from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo). Results Our data showed that the prognostic index (PI) contained 17 mRNAs and one miRNA. According to the best normalized cut‐off of PI (0.0247), the hazard ratio of the PI was 3.40 (95% confidence interval = 2.33–4.96). Moreover, when clinical factors were introduced, the PI was still the most significant index. In addition, only two Gene Ontology terms with p < 0.05 were reported. Furthermore, validation implied that, using our 18‐gene signature, only hazard ratio = 1.36 (95% confidence interval = 1.01–1.83) was significant compared to the other three groups of gene biomarkers. Conclusions The 18‐gene signature selected based on data from the TCGA database had an effective prognostic value for LUSC patients.

show abstract

Blood‐Based Biomarkers for the Diagnosis and Prognosis of Cancer

Bandyopadhayaya

Mandal

2020

Precision Medicine in Oncology

View full text Add to dashboard Cite

Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of colorectal cancer

Cited by 16 publications

References 51 publications

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

Anti‐p53 autoantibody in blood as a diagnostic biomarker for colorectal cancer: A meta‐analysis

Identification of 17 mRNAs and a miRNA as an integrated prognostic signature for lung squamous cell carcinoma

Blood‐Based Biomarkers for the Diagnosis and Prognosis of Cancer

Contact Info

Product

Resources

About